Project details
Japanese biopharmaceutical start-up seeks investment
| Project region | Japan |
|---|---|
| Industry | Biomedicine |
| Total value of the target | N/A |
| Expected target net rate of return after deducting all taxes and fees | N/A |
| Validity period of pending order | 365 |
CONTACT ADVISOR
| Project highlights | tumor antigen peptide vaccines - good safety and efficacy data |
|---|---|
| Project description |
The Japanese biopharmaceutical start-up is developing tumor antigen peptide vaccines and authorizing immunologic adjuvants. The tumor antigen peptide vaccines are tumor polypeptide antigens (HSP70/GPC3 peptides) which can be combined with three different types of white blood cells (HLA-A2402, HLA-A0201, HLA-A0206). The other component - immunologic adjuvants - have been recognized in clinical trials with good safety and efficacy data; it has already been applied for patent and is planning to conduct Phase 1 and Phase 2 clinical trials. |
We provide expert advisory and corporate services across Asia, guiding businesses through complex markets and regulations.
Have Any Questions?
Reach out to our local experts, we’ll respond within one business day.
Our Clients
Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.
See what our clients say about us
